SYDNEY, AUSTRALIA: Microba Life Sciences Limited (ASX:MAP), a leading provider of microbiome testing services, has announced the acquisition of Invivo Clinical Limited (Invivo), a UK-based company that offers a range of microbiome testing and intervention products. The deal is valued at approximately A$12.5 million, plus up to A$8.7 million in earn-out consideration, payable in both…